To identify vulnerabilities of PARG deficiency in BRCA2-deficient tumors, we first set out to generate PARG-deficient Brca2−/−;Trp53−/− mammary tumor cells that recapitulate the previously described phenotype of PARPi resistance (Gogola et al, 2018). The gene discussed is TP53; the disease is breast cancer.